Spera Pharma

Tokyo, Japan· Est. 2020

A Japanese CDMO providing comprehensive CMC R&D services, spun out from Takeda, with expertise in API, formulation, and analytical development.

spera-pharma.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese CDMO providing comprehensive CMC R&D services, spun out from Takeda, with expertise in API, formulation, and analytical development.

Technology Platform

An integrated CMC (Chemistry, Manufacturing, and Controls) platform offering API process development, advanced formulation technologies (modified release, solid dispersion), and analytical services, featuring specialized capabilities like 3D ED/MicroED for crystal structure analysis.

Opportunities

Growth is driven by the increasing outsourcing of CMC work by pharmaceutical companies, especially virtual and small biotechs, and the expansion of its service offerings through strategic alliances in areas like biopharmaceuticals and advanced analytics.

Risk Factors

Key risks include intense competition in the global CDMO market, reliance on a skilled but finite talent pool in Japan, and potential client concentration risk, particularly with its historical ties to Takeda.

Competitive Landscape

Spera competes with global CDMOs like Lonza, Catalent, and Thermo Fisher, as well as other Japanese CROs/CDMOs. Its primary differentiation is its deep, pharma-grade CMC expertise inherited from Takeda, offering clients a level of development sophistication typically reserved for large internal R&D teams.

More companies in Japan →